Scrip Asks…What Does 2024 Hold for Biopharma? Part 3: Manufacturing and Supply 

As we head into 2024, experts are wondering: what does this year hold for biopharma? As we look ahead on manufacturing and supply-related issues, Precision’s Anshul Mangal weighs in on expectations, improvements for delivery of cell and gene therapies, shifting the focus to sustainability, and the importance of continued access to these critical drugs.

Read the article here (subscription required).